05:45:19 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-06-26 Bokslutskommuniké 2024
2024-03-27 Kvartalsrapport 2024-Q3
2023-12-21 Kvartalsrapport 2024-Q2
2023-11-15 Extra Bolagsstämma 2024
2023-10-27 Årsstämma 2024
2023-10-13 Ordinarie utdelning PHI 0.00 SEK
2023-09-20 Kvartalsrapport 2024-Q1
2023-06-23 Bokslutskommuniké 2023
2023-05-09 Extra Bolagsstämma 2023
2023-03-28 Kvartalsrapport 2023-Q3
2022-12-21 Kvartalsrapport 2023-Q2
2022-10-31 Årsstämma 2023
2022-10-14 Ordinarie utdelning PHI 0.00 SEK
2022-09-29 Kvartalsrapport 2023-Q1
2022-06-29 Bokslutskommuniké 2022
2022-03-21 Kvartalsrapport 2022-Q3
2022-03-15 Extra Bolagsstämma 2022
2021-12-29 Kvartalsrapport 2022-Q2
2021-10-20 Extra Bolagsstämma 2021
2021-10-11 Ordinarie utdelning PHI 0.00 SEK
2021-09-29 Kvartalsrapport 2022-Q1
2021-06-24 Bokslutskommuniké 2021
2021-03-16 Kvartalsrapport 2021-Q3
2020-12-14 Kvartalsrapport 2021-Q2
2020-10-20 Årsstämma 2021
2020-10-15 Ordinarie utdelning PHI 0.00 SEK
2020-09-28 Kvartalsrapport 2021-Q1
2020-06-25 Bokslutskommuniké 2020
2020-03-12 Kvartalsrapport 2020-Q3
2019-12-17 Kvartalsrapport 2020-Q2
2019-10-16 Ordinarie utdelning PHI 0.00 SEK
2019-10-15 Årsstämma 2020
2018-09-27 Ordinarie utdelning PHI 0.00 SEK
2018-09-26 Årsstämma 2019
2018-06-18 Extra Bolagsstämma 2019
2018-06-12 Bokslutskommuniké 2018
2018-03-12 Kvartalsrapport 2018-Q3
2017-09-26 Ordinarie utdelning PHI 0.00 SEK
2017-09-25 Årsstämma 2018
2017-09-11 Kvartalsrapport 2018-Q1
2017-06-19 Bokslutskommuniké 2017
2017-03-13 Kvartalsrapport 2017-Q3
2017-01-01 Extra Bolagsstämma 2018
2016-11-30 Kvartalsrapport 2017-Q2
2016-09-06 Ordinarie utdelning PHI 0.00 SEK
2016-09-05 Kvartalsrapport 2017-Q1
2016-09-05 Årsstämma 2017
2016-06-13 Bokslutskommuniké 2016
2016-02-22 Kvartalsrapport 2016-Q3
2016-02-16 Extra Bolagsstämma 2017
2015-11-30 Kvartalsrapport 2016-Q2
2015-09-08 Ordinarie utdelning PHI 0.00 SEK
2015-09-07 Kvartalsrapport 2016-Q1
2015-09-07 Årsstämma 2016
2015-06-16 Bokslutskommuniké 2015
2015-03-16 Kvartalsrapport 2015-Q3
2014-12-01 Kvartalsrapport 2015-Q2
2014-10-07 Ordinarie utdelning PHI 0.00 SEK
2014-10-06 Kvartalsrapport 2015-Q1
2014-10-06 Årsstämma 2015
2014-06-30 Bokslutskommuniké 2014

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriMedicinteknik
Phase Holographic Imaging PHI är verksamt inom medicinteknik. Bolaget utvecklar instrument och mjukvara för time-lapse cytometri. Produkterna används för kvantitativ långtidsanalys av levande cellers dynamik, särskilt av betydelse inom cancerforskning, samt vid behandling av inflammatoriska - samt autoimmuna sjukdomar. Produkterna säljs på global nivå via bolagets distributörer och störst närvaro återfinns inom Norden. Huvudkontoret ligger i Lund.
2023-10-12 11:28:12

Phase Holographic Imaging (PHI) proudly stands behind the Wake Forest Institute for Regenerative Medicine (WFIRM) as they contend as a finalist in the National Science Foundation (https://www.nsf.gov/)'s (NSF) Regional Innovation Engines competition, with a potential award of up to $160 million.

[image]

WFIRM's groundbreaking work in regenerative medicine is now in the national spotlight, driven by the NSF's Regional Innovation Engines (NSF Engines (https://new.nsf.gov/funding/initiatives/regional-innovation-engines)) competition. The NSF, an independent federal agency and a key driver for scientific advancements in the U.S. initiated this competition to foster tech-driven innovation ecosystems. Out of numerous contenders, 16 finalists remain, each selected for their potential to reshape key technology areas and address pressing societal challenges.

PHI is an integral part of the Regenerative Medicine Development Organization (ReMDO), located at WFIRM, which is committed to innovating Regenerative Medicine Clinical Manufacturing. PHI's collaboration with its valuable Alliance partners SAS, QIAGEN, and BioSpherix underscores the shared drive to revolutionize regenerative medicine. With PHI's biomedical engineer stationed at WFIRM, the partnership has made significant strides in running live cell experiments and collaborative efforts.

[image]

US PHI Inc. President Håkan Rosvall attended, upon invitation, an NSF meeting yesterday to support WFIRM's application for the government grant. He emphasizes the pivotal role of collaborations like that of PHI and WFIRM:

"It's exhilarating to see this great collaboration in regenerative medicine. The synergy between PHI, our dedicated ReMDO partners, and WFIRM showcases what's possible when innovators unite."

The NSF's competition is not merely about financial incentives. It represents a national effort to recognize organizations that can become giants in their respective industries, like Facebook or Tesla. Several of the 16 finalists will be announced this winter as the grant winners.